SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-008625
Filing Date
2021-01-14
Accepted
2021-01-14 07:53:13
Documents
18
Period of Report
2021-01-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d112316d8k.htm   iXBRL 8-K 35395
2 EX-1.1 d112316dex11.htm EX-1.1 233305
3 EX-5.1 d112316dex51.htm EX-5.1 7409
4 EX-99.1 d112316dex991.htm EX-99.1 8937
5 EX-99.2 d112316dex992.htm EX-99.2 9318
9 GRAPHIC g112316g0114062203482.jpg GRAPHIC 6757
10 GRAPHIC g112316g0114083656032.jpg GRAPHIC 6757
  Complete submission text file 0001193125-21-008625.txt   516187

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA aldx-20210112.xsd EX-101.SCH 3066
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20210112_lab.xml EX-101.LAB 18138
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20210112_pre.xml EX-101.PRE 11405
11 EXTRACTED XBRL INSTANCE DOCUMENT d112316d8k_htm.xml XML 3362
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 21527512
SIC: 2834 Pharmaceutical Preparations